ModifiedUnitedHealthcarePolicy N/A

Ductoscopy, nipple aspirate fluid, and fiberoductoscopy for pathological nipple discharge/breast cancer detection

This UnitedHealthcare medical policy provides coverage interpretation and supporting information for ductoscopy, nipple aspirate fluid analysis, fiberoductoscopy, and related procedures for evaluating pathological nipple discharge and breast cancer detection; includes references, state applicability notes, and revision history. It instructs users to follow federal/state/contractual plan terms where they differ.

Policy Summary

PayerUnitedHealthcare

PolicyDuctoscopy, nipple aspirate fluid, and fiberoductoscopy for pathological nipple discharge/breast cancer detection

Policy CodePolicy N/A

Change TypeState applicability and template updatessupporting information refreshed

Effective Date

Next Review Date

Key ActionBefore using this policy, check the federal, state or contractual requirements for benefit plan coverage; in the event of a conflict, those requirements govern.

SourceLink

POLICY UPDATE CHANGES

04/01/2026, Summary of Changes = Template Update: Removed content/language pertaining to the state of Louisiana.

11/01/2025, Summary of Changes = Application Nebraska and North Carolina: Added language to indicate this Medical Policy does not apply to the states of Nebraska and North Carolina; refer to the state-specific policy versions.

08/01/2025, Summary of Changes = Supporting Information: Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information; Archived previous policy version CS029.S

3Policy revisions listed

2States explicitly excluded

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy addresses the subject of Ductoscopy, nipple aspirate fluid, and fiberoductoscopy for pathological nipple discharge/breast cancer detection and provides a mixed coverage stance — the policy contains informational coverage interpretation and clinical evidence but does not uniformly endorse these procedures for screening or diagnosis. This document is intended to support interpretation of UnitedHealthcare standard benefit plans and includes state applicability notes and revision history.

This policy is informational and must be reconciled with applicable federal, state, or contractual plan terms; in the event of any conflict, those federal/state/contractual requirements govern. Before using this policy, check the relevant benefit plan terms and any state-specific policy versions.

UnitedHealthcare Medical Policies are intended to be used with independent professional medical judgment. UnitedHealthcare may use third-party tools (for example, InterQual criteria) to assist in administering benefits; these tools and the policy should be applied consistent with contractual and regulatory requirements.

Surface statistics and dates

Policy revisions listed3

States explicitly excluded2

Applicability / State Exceptions

Policy application depends on state-specific policy versions and contractual requirements:

Policy applies to UnitedHealthcare standard benefit plans except where federal, state or contractual requirements differ

In case of conflict, the federal, state or contractual requirements govern

State exceptions

This Medical Policy does not apply to the state of Nebraska
Refer to Nebraska-specific policy version
This Medical Policy does not apply to the state of North Carolina
Refer to North Carolina-specific policy version
Removed content/language pertaining to the state of Louisiana (04/01/2026 template update)
Administrative change to state-specific language

Background & Evidence

This policy includes references to clinical studies and reviews concerning nipple aspirate fluid (NAF) analysis, ductoscopy/ductal lavage, and fiberoptic ductoscopy (FDS) for evaluation of pathological nipple discharge and breast disease. The cited literature encompasses systematic reviews, observational studies, randomized trials, and device/regulatory information examining diagnostic accuracy, sample adequacy, technical feasibility, and clinical utility.

The policy emphasizes that evidence to date has limitations: NAF and ductal lavage studies report variable sensitivity and high rates of inadequate samples; ductoscopy and fiberoductoscopy studies demonstrate technical feasibility and promising diagnostic correlations in some series but are limited by single-center designs, retrospective methods, heterogeneity, and uncertain impact on outcomes such as earlier detection or mortality.

Accordingly, the policy is informational and directs readers to reconcile these findings with federal/state/contractual coverage requirements and to apply independent professional medical judgment when considering these techniques.

Evidence summary

Referenced studies and reviewsMultiple citations (2005-2025) including systematic reviews and observational studies on ductoscopy, nipple aspirate fluid biomarkers, and fiberoductoscopy diagnostic value (examples: systematic reviews/meta-analyses 2016, 2021; observational and retrospective studies 2005-2025).

Provider Actions

Documentation Required

Follow applicable federal/state/contractual requirements

Before using this policy, check the federal, state or contractual requirements for benefit plan coverage; in the event of a conflict, those requirements govern.

Documentation Required

Use independent professional judgment and referenced tools

UnitedHealthcare Medical Policies are informational and intended to be used with independent professional medical judgment; UnitedHealthcare may use third-party tools (e.g., InterQual criteria) to assist in administering benefits.

Supporting Evidence & References

Placeholder — referenced studies and reviews summary: Populateers should summarize key citation themes from the evidence set (multiple citations spanning 2005–2025) without listing full citations here. Key themes to render include: (1) ductoscopy and fiberoductoscopy diagnostic value and limitations; (2) nipple aspirate fluid biomarkers and cytology diagnostic performance, including sample adequacy and sensitivity/specificity concerns; and (3) systematic reviews/meta-analyses and observational studies assessing ductoscopy/ductal lavage/NAF.

Do not enumerate full bibliographic citations in this block; detailed references may be presented elsewhere in source documents. Use the evidence list to guide inclusion of themes such as diagnostic accuracy variability, heterogeneity across studies, technical challenges and learning curve for FDS, and the overall informational (investigational/insufficient-evidence) status of these procedures for routine screening or diagnostic replacement.

Revision History

2025-11-01change

Application Nebraska and North Carolina: Added language to indicate this Medical Policy does not apply to the states of Nebraska and North Carolina; refer to the state-specific policy versions.

2025-08-01change

Supporting Information: Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information; Archived previous policy version CS029.S

2026-04-01changeLatest